Sino Biopharmaceutical Limited
HKSE: 1177.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- S. Y. Tse
- Employees
- 24,379
- Headquarters
- Wan Chai, Hong Kong SAR China
- IPO year
- 2003
- Market cap
- HK$97.1B
- Website
- https://www.sinobiopharm.com
Loading 1177…
Loading profile data…Frequently asked questions about 1177
What does Sino Biopharmaceutical Limited (1177.HK) do?
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkesh...
Where does 1177.HK trade?
Sino Biopharmaceutical Limited (1177.HK) trades on the Hong Kong Stock Exchange.
What sector is 1177.HK in?
Sino Biopharmaceutical Limited (1177.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sino Biopharmaceutical Limited?
S. Y. Tse is the chief executive officer of Sino Biopharmaceutical Limited (1177.HK).
Where is Sino Biopharmaceutical Limited headquartered?
Sino Biopharmaceutical Limited is headquartered in Hong Kong SAR China.
Does 1177.HK pay a dividend?
Yes — Sino Biopharmaceutical Limited (1177.HK) paid a trailing twelve-month dividend of HKD 0.09 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 1177.HK go public?
Sino Biopharmaceutical Limited (1177.HK) completed its initial public offering in 2003.